绿谷制药携手行业智库 助力中医药传承创新

2017-08-25 佚名 MedSci原创

-“中药管理与发展策略”系列活动走进河北

石家庄2017年8月24日电 /美通社/ -- 2017年8月19日,由中华中医药学会和上海绿谷制药有限公司共同举办的“紧跟政策、把握机遇、发扬国粹 -- 中药管理与发展策略”系列活动在河北石家庄举办。

中华中医药学会原副秘书长谢钟、河北省食品药品监督管理局原副局长刘骁悍、河北省中医药管理局中医处处长高庆丰出席开幕式并讲话,来自河北省十多个地市的共计70多名医院院长、药剂科负责人及临床专家参加会议

会议现场座无虚席" border="0" alt="会议现场座无虚席" align="middle" src="http://photos.prnasia.com/prnvar/20170823/1925911-1-a " />
会议现场座无虚席

国家中医药管理局医政司原副司长、中国中医科学院望京医院原院长陈珞珈、中国科学院上海药物研究所教授宣利江及国家卫生计生委卫生发展研究中心信息研究室主任程龙等中医药管理与政策研究专家、学者围绕中医药发展战略政策解读和战略思考、新形势下中医药发展的挑战与应对等话题展开深入研讨。

高庆丰在讲话中指出,近年来,河北省实施了一系列扶持中医药发展的重大举措,中医药医疗、保健、科研、教育、产业、文化“六位一体”全面发展的新格局正逐步形成,中医药产业已经成为河北省战略性新兴产业。去年,河北省人民政府先后印发河北省贯彻《中医药发展战略规划纲要(2016-2030年)》实施方案、《河北省中医药发展“十三五”规划》,在今后的五年里,河北将利用前所未有的发展机遇,以满足人民群众中医药健康需求为出发点和落脚点,全面推进中医药供给侧结构性改革,不断提升中医药服务水平,增强服务的可及性和可得性,真正让中医药成果惠及百姓,增进人民健康福祉。

高庆丰表示,此次活动提供了让多名专家与河北中医医院管理者们深入交流与研讨的良好平台,希望大家用实际行动为实现“到2020年人人享有基本中医药服务,初步把河北建成中医药强省”的目标做出更大贡献。

河北省中医药管理局中医处处长高庆丰讲话
河北省中医药管理局中医处处长高庆丰讲话

与会代表纷纷表示,专家对于中药管理与发展策略的分享解读,让大家对当前中医药行业发展的大政策理解与改革思路有了进一步的提升。对于中医药也有了更深层次的认识。

作为一家以创新研发为驱动力的中国现代药企,多年来绿谷制药积淀了中国传统文化最深层的智慧,实现了对中国优秀文化经典的传承与创新。注射用丹参多酚酸盐就是现代科技演绎传统经典、创新天然药物的成功典范,从物质基础、工艺质控、作用机制、有效性和安全性等诸多方面实现了突破和创新。中药现代化是绿谷制药打造绿色精准医疗平台的重要路径。绿谷制药将持续助力推动中药现代化基础研究,为我国中医药事业的伟大复兴贡献更多力量。

版权声明:
本网站所有内容来源注明为“williamhill asia 医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于williamhill asia 医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“williamhill asia 医学”。其它来源的文章系转载文章,或“williamhill asia 号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与williamhill asia 联系,williamhill asia 将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1675547, encodeId=046d16e5547ec, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Mon May 14 08:18:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796815, encodeId=06281e968153c, content=<a href='/topic/show?id=969121500e5' target=_blank style='color:#2F92EE;'>#中医药传承创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21500, encryptionId=969121500e5, topicName=中医药传承创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Sat Jul 07 00:18:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285403, encodeId=3b0b128540363, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Aug 27 00:18:00 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409032, encodeId=f20814090320f, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Aug 27 00:18:00 CST 2017, time=2017-08-27, status=1, ipAttribution=)]
    2018-05-14 lishizhe
  2. [GetPortalCommentsPageByObjectIdResponse(id=1675547, encodeId=046d16e5547ec, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Mon May 14 08:18:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796815, encodeId=06281e968153c, content=<a href='/topic/show?id=969121500e5' target=_blank style='color:#2F92EE;'>#中医药传承创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21500, encryptionId=969121500e5, topicName=中医药传承创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Sat Jul 07 00:18:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285403, encodeId=3b0b128540363, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Aug 27 00:18:00 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409032, encodeId=f20814090320f, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Aug 27 00:18:00 CST 2017, time=2017-08-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1675547, encodeId=046d16e5547ec, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Mon May 14 08:18:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796815, encodeId=06281e968153c, content=<a href='/topic/show?id=969121500e5' target=_blank style='color:#2F92EE;'>#中医药传承创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21500, encryptionId=969121500e5, topicName=中医药传承创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Sat Jul 07 00:18:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285403, encodeId=3b0b128540363, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Aug 27 00:18:00 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409032, encodeId=f20814090320f, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Aug 27 00:18:00 CST 2017, time=2017-08-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1675547, encodeId=046d16e5547ec, content=<a href='/topic/show?id=8e7d258696c' target=_blank style='color:#2F92EE;'>#传承#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25869, encryptionId=8e7d258696c, topicName=传承)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=85d827261473, createdName=lishizhe, createdTime=Mon May 14 08:18:00 CST 2018, time=2018-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1796815, encodeId=06281e968153c, content=<a href='/topic/show?id=969121500e5' target=_blank style='color:#2F92EE;'>#中医药传承创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21500, encryptionId=969121500e5, topicName=中医药传承创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6e7948, createdName=李研东, createdTime=Sat Jul 07 00:18:00 CST 2018, time=2018-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1285403, encodeId=3b0b128540363, content=<a href='/topic/show?id=77903209422' target=_blank style='color:#2F92EE;'>#创新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32094, encryptionId=77903209422, topicName=创新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512a199, createdName=lilianxiang, createdTime=Sun Aug 27 00:18:00 CST 2017, time=2017-08-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409032, encodeId=f20814090320f, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Aug 27 00:18:00 CST 2017, time=2017-08-27, status=1, ipAttribution=)]
    2017-08-27 cathymary